Evaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and Zidovudine
|ClinicalTrials.gov Identifier: NCT00000732|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : March 16, 2012
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Sulfamethoxazole-Trimethoprim Drug: Zidovudine||Not Applicable|
AZT has been effective in treating some patients with AIDS, and SMX/TMP is an antibiotic combination which is useful in preventing or treating Pneumocystis carinii pneumonia (PCP), which is an important cause of disease and death in patients with AIDS. It is important to know how drugs interact in patients because addition of a second drug may change the speed at which a drug is eliminated from the body, and cause increased toxic effects or decreased therapeutic effects.
Patients take AZT every 4 hours and/or SMX/TMP every 12 hours by mouth for 4 days as outpatients and then come into the clinical research center for 2 days of studies. On day 5 the final dose of medicine is given orally (SMX/TMP) or by intravenous infusion (AZT). Blood samples are drawn 10-20 times over a period of 12 hours and urine is collected for 36 hours. Concentrations of the drugs in the blood and urine samples are determined. This sequence is repeated twice, so that each patient takes AZT alone, SMX/TMP alone, and the combination of AZT and SMX/TMP over a period of about 3 weeks. Patients may be included in the study if they are asymptomatic, or have been diagnosed with ARC or AIDS, but not if they have PCP or any other severe opportunistic infection.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||10 participants|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of the Interaction Between Low Dose Trimethoprim/Sulfamethoxazole and Zidovudine|
|Actual Study Completion Date :||May 1990|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000732
|United States, Pennsylvania|
|Univ of Pittsburgh Med School|
|Pittsburgh, Pennsylvania, United States|
|Study Chair:||Ptachcinski R|